PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
Healio announces appointment of first chief AI officer
Joan-Marie Stiglich, ELS, who has been with The Wyanoke Group for 31 years, will oversee Healio AI in the newly-created role, chief AI officer.Healio’s flagship AI product, Healio AI is a generative tool that is updated daily to deliver evidence-based …
Oral micronutrients show no impact on GA lesion growth
ORLANDO — Oral micronutrient supplementation showed no benefit on geographic atrophy lesion growth among a patient group from the OAKS and DERBY trials, according to a speaker.“We have had many post hoc analyses of recent trials that have shown that, p…
Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today announced that the U.S…
The 12 Dangers of Christmas
Echoing the 12 Days of Christmas, this festive guide outlines the seasonal risks clinicians can help patients avoid. Medscape News UK
Aflibercept 8 mg Promising Alternative to 2 mg for PCV
Aflibercept 8 mg provides similar outcomes for vision and eye structure as the 2-mg dose in patients with polypoidal choroidal vasculopathy, a recent study finds. Medscape Medical News